About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Molecular Imaging and Therapy research group focuses its activity on deepening the molecular bases and developing new areas of research in molecular signaling pathways and the identification of new theranostic targets.
We promote the confluence of basic and clinical researchers, experts in imaging and molecular biology to provide:
In this context, the creation of a translational imaging unit constitutes a basic objective for the development of research aimed at the personalized treatment of patients.
The group is made up of medical specialists in molecular imaging, chemists and pharmacists specializing in tracer synthesis, and biomedical engineers and physicists specializing in image processing and tomography equipment. These are affiliated with different institutions, such as the Vall d'Hebron Research Institute (VHIR), the Vall d'Hebron University Hospital (HUVH) and the Institute of Diagnostic Imaging (IDI).
IP: Ramón Vilallonga Puy Collaborators: Carlos Petrola Chacón, Mercedes Pérez Lafuente, Elisa Merino Peña, Nuria Roson Gradaille, Laura Puente Ramo, Marta Comas Martinez, Alba Rojano Toimil, Arturo Cirera De Tudela, Alba Maria Jiménez Masip Funding agency: Instituto de Salud Carlos III Funding: 171820 Reference: PI22/00880 Duration: 01/01/2023 - 31/12/2026
IP: José Raul Herance Camacho Collaborators: Sofia Rodriguez Fernandez, Sergi Velasco Vila, Cristina Gamez Cenzano, Elena Maria Diaz Medina, Jana Vidal Otero, Carolina Aparicio Gomez, Emily Betancourt Fernández Funding agency: The Innovative Medicines Initiative Funding: 514560 Reference: IMMUNE-IMAGE_IMI22018 Duration: 01/10/2019 - 31/03/2027
IP: Jordi Bove Badell Collaborators: Miquel Vila Bover, Alejandro Ferré Masó, Oriol de Fabregues-Boixar Nebot, Carles Lorenzo Bosquet, Antonio Palasi Franco Funding agency: Instituto de Salud Carlos III Funding: 165770 Reference: PI21/01358 Duration: 01/01/2022 - 30/06/2026
IP: Lucas Moreno Martín-Retortillo Collaborators: Soledad Gallego Melcón, Cristina Gamez Cenzano, Aroa Soriano Fernández, Luis Riera Soler, Miguel Segura Ginard, Carlota Aguilera Ordoñez Funding agency: Instituto de Salud Carlos III Funding: 826760.77 Reference: ICI21/00076 Duration: 01/01/2022 - 30/06/2026
Researchers incorporate advanced cardiovascular prediction algorithms into cardiac imaging software, enabling the automatic calculation of the risk of serious complications during the routine analysis of cardiac studies.
Researchers from the centre took part in international debates on AI in healthcare, spin-offs emerging from research were presented, and several initiatives linked to VHIR received recognition in the field of entrepreneurship.
ImmunoPET enables in vivo detection of LIF expression, a molecule linked to tumour growth, immune evasion and treatment resistance.
